Labopharm Inc. (DDSS) has granted GlaxoSmithKline (GSK) exclusive rights to distribute its once-daily tramadol product in Mexico. The Laval, Que. pharmaceutical company said the agreement expands the existing licensing and distribution arrangement between it and Glaxo, entered into in September 2005, for 20 Latin American and Caribbean countries.
MarketWatch
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA OKs Device for Treating Heart Failure
The physician tests and programs the device after implementation.
Illinois Man Gets Five Years in Phony Pharmacy Scam
Calhoun obtained scrips for Arixtra, an expensive daily injection used to treat or prevent blood clots.
FDAnews Drug Daily Bulletin
LABOPHARM GRANTS GLAXO ONCE-DAILY TRAMADOL RIGHTS IN MEXICO
June 1, 2006
